{"id":"NCT00529087","sponsor":"Bausch Health Americas, Inc.","briefTitle":"Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain","officialTitle":"A Mulitcenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation in Subjects With Chronic Non-Malignant Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2007-09-14","resultsPosted":"2010-05-11","lastUpdate":"2019-11-25"},"enrollment":460,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Constipation"],"interventions":[{"type":"DRUG","name":"N-methylnaltrexone bromide (MOA-728)","otherNames":[]},{"type":"OTHER","name":"placebo","otherNames":[]}],"arms":[{"label":"1","type":"PLACEBO_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"}],"summary":"The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with chronic non-malignant pain who have Opioid-Induced Constipation (OIC).","primaryOutcome":{"measure":"Percentage of Patients Having a Rescue-free Bowel Movement (RFBM) Within 4 Hours of the First Dose","timeFrame":"up to 4 hours","effectByArm":[{"arm":"MOA-728 QD and MOA-728 QOD","deltaMin":34.2,"sd":null},{"arm":"Placebo","deltaMin":9.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":78,"countries":["United States"]},"refs":{"pmids":["33788162","21810165"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":150},"commonTop":["Abdominal pain","Nausea","Diarrhoea","Hyperhidrosis","Vomiting"]}}